目的 探討明目蒺藜丸聯(lián)合玻璃酸鈉滴眼液治療干眼癥的臨床療效。方法 選取2021年7月—2023年1月在中國人民解放軍中部戰(zhàn)區(qū)總醫(yī)院診治的78例干眼癥患者，根據(jù)用藥方案的不同將所有患者分為對照組和治療組，每組各39例。對照組給予玻璃酸鈉滴眼液，1滴/次，3次/d；治療組在對照組治療基礎(chǔ)上口服明目蒺藜丸，9 g/次，2次/d。兩組均治療8周。觀察兩組的臨床療效和臨床癥狀改善時(shí)間，比較兩組治療前后視功能相關(guān)生命質(zhì)量量表（NEI-VFQ-25）評分、視功能損害眼病患者生存質(zhì)量量表（SQOL DVI）評分、眼表疾病量表（OSDI）評分、眼表功能指標(biāo)、淚液細(xì)胞因子的變化情況。結(jié)果 治療后，治療組的總有效率是97.44%，顯著高于對照組的79.49%（P＜0.05）。治療后，治療組眼睛干澀感、異物感、疲勞感、畏光、灼燒感改善時(shí)間上均顯著短于對照組（P＜0.05）。治療后，兩組NEI-VFQ-25評分、SQOL DVI評分均顯著升高，而中國干眼問卷量表評分、OSDI量表評分均顯著降低（P＜0.05）；治療后，治療組患者相關(guān)量表評分改善均優(yōu)于對照組（P＜0.05）。治療后，兩組患者淚膜破裂時(shí)間（FBUT）、SⅠt均較治療前顯著升高，而角膜熒光素染色（FL）評分顯著降低（P＜0.05）；治療后，治療組眼表功能指標(biāo)改善均優(yōu)于對照組（P＜0.05）。治療后，兩組淚液中白細(xì)胞介素-1β（IL-1β）、白細(xì)胞介素-6（IL-6）、腫瘤壞死因子-α（TNF-α）均顯著降低，而溶菌酶、表皮生長因子（EGF）、乳鐵蛋白（LF）均顯著顯著升高（P＜0.05）；治療后，治療組淚液細(xì)胞因子改善均優(yōu)于對照組（P＜0.05）。結(jié)論 明目蒺藜丸聯(lián)合玻璃酸鈉滴眼液治療干眼癥可有效改善臨床癥狀，改善眼表功能及淚液分泌，下調(diào)淚液細(xì)胞因子水平，提高生活質(zhì)量，有著良好的臨床應(yīng)用價(jià)值。

Objective To explore the clinical efficacy of Mingmu Jili Pills combined with Sodium Hyaluronate Eye Drops in treatment of dry eye. Methods A total of 78 patients with dry eye diagnosed and treated in Chinese People’s Liberation Army Central Theater Command General Hospital from July 2021 to January 2023 were selected, and all patients were divided into control group and treatment group according to different medication regiments, with 39 cases in each group. Patients in the control group were given Sodium Hyaluronate Eye Drops, 1 drop/time, 3 times daily. Patients in the treatment group were po administered with Mingmu Jili Pills on the basis of the control group, 9 g/time, twice daily. Both groups were treated for 8 weeks. The clinical efficacy and improvement time of clinical symptoms of the two groups were observed, and the changes of NEI-VFQ-25 scores, SQOL DVI scores, OSDI scores, ocular surface function indexes and cytokines in tears before and after treatment were compared between the two groups. Results After treatment, the total effective rate of the treatment group was 97.44%, which was significantly higher than that of the control group (79.49%, P< 0.05). After treatment, the improvement time of dry eyes, foreign body sensation, fatigue, photophobia and burning sensation in the treatment group was significantly shorter than that in the control group (P < 0.05). After treatment, NEI-VFQ-25 scores and SQOL DVI scores of both groups were significantly increased, but scores of China Dry Eye Questionnaire scale and OSDI scale were significantly decreased (P < 0.05). After treatment, the improvement of relevant scale scores in the treatment group was better than that in the control group (P < 0.05). After treatment, tear film rupture time (FBUT) and SⅠt were significantly increased in both groups compared with before treatment, but corneal fluorescein staining (FL) score was significantly decreased (P < 0.05). After treatment, the improvement of ocular surface function index in treatment group was better than that in control group (P < 0.05). After treatment, the levels of interleukin-1β (IL-1β), interleukin-6 (IL-6), and tumor necrosis factor-α (TNF-α) in tears of both groups were significantly decreased, but lysozyme, epidermal growth factor (EGF) and lactoferrin (LF) were significantly increased (P< 0.05). After treatment, the improvement of tear cytokines in the treatment group was better than that in the control group (P < 0.05). Conclusion Mingmu Jili Pills combined with Sodium Hyaluronate Eye Drops can effectively improve clinical symptoms in treatment of dry eye, and can improve eye surface function and tear secretion, downregulate the expression of tear cytokines, and improve life quality with good clinical application value.

R988.1